摘要
The compelling demand of a consummate analgesic medication without addiction is rising due to the clinical mistreatment. Additionally, the series of severe untoward effects usually deterred the utilization while coping with serious pain. As a possible turning point, we revealed that compound 14 is a dual agonist of mu opioid receptor (MOR) and nociceptin-orphanin FQ opioid peptide (NOP) receptor in this study. More importantly, compound 14 achieves pain relieving at very small doses, meanwhile, reduces several unwanted side effects such as constipation, reward, tolerance and withdrawal effects. Here, we evaluated the antinociception and side effects of this novel compound from wild type and humanized mice to further develop a safer prescription analgesic drug.
原文 | English |
---|---|
文章編號 | 115608 |
期刊 | European Journal of Medicinal Chemistry |
卷 | 258 |
DOIs | |
出版狀態 | Published - 2023 10月 5 |
All Science Journal Classification (ASJC) codes
- 藥理
- 藥物發現
- 有機化學